Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389180 | 0.90 | TSHR (0.63) | TSHRCETPPKMALDH1A1FOLH1 | |
| SCHEMBL17034260 | 0.83 | TSHR (0.55) | TSHRCETPPKMALDH1A1 | |
| SCHEMBL8619121 | 0.81 | TSHR (0.57) | TSHRCETPPKMALDH1A1FOLH1 | |
| SCHEMBL218693 | 0.81 | TSHR (0.57) | TSHRCETPALDH1A1FOLH1SRC | |
| SCHEMBL12313535 | 0.79 | TSHR (0.55) | TSHRCETPPKMALDH1A1FOLH1 | |
| SCHEMBL12746424 | 0.79 | TSHR (0.59) | TSHRCETPPKMALDH1A1FOLH1 | |
| SCHEMBL3367142 | 0.78 | TSHR (0.63) | TSHRCETPPKMALDH1A1FOLH1 | |
| SCHEMBL26569501 | 0.78 | TSHR (0.53) | TSHRCETPPKMSRCELANE | |
| SCHEMBL4040892 | 0.78 | TSHR (0.81) | TSHRCETPALDH1A1FOLH1SRC | |
| SCHEMBL9891064 | 0.77 | TSHR (0.49) | TSHRCETPPKMALDH1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | TSHR 2620/4885CETP 3910/4885PKM 1274/4885 |
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | ERG28, PDXK, PAH | TSHR 4387/4885CETP 4516/4885PKM 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.